A citation-based method for searching scientific literature

B T Cooper, J O Murphy, V Sacchini, S C Formenti. Ann Oncol 2013
Times Cited: 4







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
50

Common variants in ZNF365 are associated with both mammographic density and breast cancer risk.
Sara Lindström, Celine M Vachon, Jingmei Li, Jajini Varghese, Deborah Thompson, Ruth Warren, Judith Brown, Jean Leyland, Tina Audley, Nicholas J Wareham,[...]. Nat Genet 2011
87
25

Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.
Shahana Ahmed, Gilles Thomas, Maya Ghoussaini, Catherine S Healey, Manjeet K Humphreys, Radka Platte, Jonathan Morrison, Melanie Maranian, Karen A Pooley, Robert Luben,[...]. Nat Genet 2009
378
25

Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.
Pascal Pujol, Christine Lasset, Pascaline Berthet, Catherine Dugast, Suzette Delaloge, Jean-Pierre Fricker, Isabelle Tennevet, Nathalie Chabbert-Buffet, Pascale This, Karen Baudry,[...]. Fam Cancer 2012
20
25

Body image and psychological distress after prophylactic mastectomy and breast reconstruction in genetically predisposed women: a prospective long-term follow-up study.
Mariska den Heijer, Caroline Seynaeve, Reinier Timman, Hugo J Duivenvoorden, Kathleen Vanheusden, Madeleine Tilanus-Linthorst, Marian B E Menke-Pluijmers, Aad Tibben. Eur J Cancer 2012
47
25


Alternatives to risk-reducing surgery for ovarian cancer.
A Gadducci, C Sergiampietri, R Tana. Ann Oncol 2013
13
25

Tumour morphology of early-onset breast cancers predicts breast cancer risk for first-degree relatives: the Australian Breast Cancer Family Registry.
Gillian S Dite, Enes Makalic, Daniel F Schmidt, Graham G Giles, John L Hopper, Melissa C Southey. Breast Cancer Res 2012
9
25

Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients.
Dawn L Hershman, Lawrence H Kushi, Theresa Shao, Donna Buono, Aaron Kershenbaum, Wei-Yann Tsai, Louis Fehrenbacher, Scarlett Lin Gomez, Sunita Miles, Alfred I Neugut. J Clin Oncol 2010
515
25

Overview of the main outcomes in breast-cancer prevention trials.
J Cuzick, T Powles, U Veronesi, J Forbes, R Edwards, S Ashley, P Boyle. Lancet 2003
649
25

Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2.
Nancie Petrucelli, Mary B Daly, Gerald L Feldman. Genet Med 2010
188
25

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Shahneen K Sandhu, William R Schelman, George Wilding, Victor Moreno, Richard D Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Forster, Aurelius Omlin,[...]. Lancet Oncol 2013
355
25

Resistance to PARP-Inhibitors in Cancer Therapy.
Alicia Montoni, Mihaela Robu, Emilie Pouliot, Girish M Shah. Front Pharmacol 2013
68
25


The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer.
Kim Tran, Renee Risingsong, Darlene B Royce, Charlotte R Williams, Michael B Sporn, Patricia A Pioli, Lalji K Gediya, Vincent C Njar, Karen T Liby. Carcinogenesis 2013
27
25

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
627
25

Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer.
Karen T Liby, Darlene B Royce, Renee Risingsong, Charlotte R Williams, Anirban Maitra, Ralph H Hruban, Michael B Sporn. Cancer Prev Res (Phila) 2010
67
25

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
952
25

Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients.
Li-Heng Yang, Hsin-Shun Tseng, Che Lin, Li-Sheng Chen, Shou-Tung Chen, Shou-Jen Kuo, Dar-Ren Chen. J Breast Cancer 2012
30
25

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
C Davies, J Godwin, R Gray, M Clarke, D Cutter, S Darby, P McGale, H C Pan, C Taylor, Y C Wang,[...]. Lancet 2011
25

A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma.
Agop Y Bedikian, Nicholas E Papadopoulos, Kevin B Kim, Wen-Jen Hwu, Jade Homsi, Michelle R Glass, Suzanne Cain, Patrick Rudewicz, Laurent Vernillet, Patrick Hwu. Cancer Invest 2009
57
25

The role of BRCA mutation testing in determining breast cancer therapy.
Alison H Trainer, Craig R Lewis, Kathy Tucker, Bettina Meiser, Michael Friedlander, Robyn L Ward. Nat Rev Clin Oncol 2010
67
25

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Joyce F Liu, Sara M Tolaney, Michael Birrer, Gini F Fleming, Mary K Buss, Suzanne E Dahlberg, Hang Lee, Christin Whalen, Karin Tyburski, Eric Winer,[...]. Eur J Cancer 2013
109
25

The evolution of melanoma resistance reveals therapeutic opportunities.
Meghna Das Thakur, Darrin D Stuart. Cancer Res 2013
42
25

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth Swenerton, André Robidoux, Katia Tonkin, Hal Hirte, David Huntsman, Mark Clemons, Blake Gilks,[...]. Lancet Oncol 2011
778
25

PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
Shaveta Vinayak, James M Ford. Curr Breast Cancer Rep 2010
18
25

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Kelly-Anne Phillips, Roger L Milne, Matti A Rookus, Mary B Daly, Antonis C Antoniou, Susan Peock, Debra Frost, Douglas F Easton, Steve Ellis, Michael L Friedlander,[...]. J Clin Oncol 2013
109
25

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
25

Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
Rebecca A Dent, Geoffrey J Lindeman, Mark Clemons, Hans Wildiers, Arlene Chan, Nicole J McCarthy, Christian F Singer, Elizabeth S Lowe, Claire L Watkins, James Carmichael. Breast Cancer Res 2013
129
25

An intermittent approach for cancer chemoprevention.
Xiangwei Wu, Scott M Lippman. Nat Rev Cancer 2011
35
25

The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
Mara H Rendi, Nanjoo Suh, William W Lamph, Stan Krajewski, John C Reed, Richard A Heyman, Andrew Berchuck, Karen Liby, Renee Risingsong, Darlene B Royce,[...]. Cancer Res 2004
51
25

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
O A Khan, M Gore, P Lorigan, J Stone, A Greystoke, W Burke, J Carmichael, A J Watson, G McGown, M Thorncroft,[...]. Br J Cancer 2011
82
25

Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Ruth Plummer, Christopher Jones, Mark Middleton, Richard Wilson, Jeffrey Evans, Anna Olsen, Nicola Curtin, Alan Boddy, Peter McHugh, David Newell,[...]. Clin Cancer Res 2008
271
25

Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.
Jason A Zell, Daniel Pelot, Wen-Pin Chen, Christine E McLaren, Eugene W Gerner, Frank L Meyskens. Cancer Prev Res (Phila) 2009
45
25

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Kerryn W Reding, Jonine L Bernstein, Bryan M Langholz, Leslie Bernstein, Robert W Haile, Colin B Begg, Charles F Lynch, Patrick Concannon, Ake Borg, Sharon N Teraoka,[...]. Breast Cancer Res Treat 2010
39
25


Roles of BRCA1 and its interacting proteins.
C X Deng, S G Brodie. Bioessays 2000
241
25

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Cherrie K Donawho, Yan Luo, Yanping Luo, Thomas D Penning, Joy L Bauch, Jennifer J Bouska, Velitchka D Bontcheva-Diaz, Bryan F Cox, Theodore L DeWeese, Larry E Dillehay,[...]. Clin Cancer Res 2007
558
25

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.
Nuala McCabe, Nicholas C Turner, Christopher J Lord, Katarzyna Kluzek, Aneta Bialkowska, Sally Swift, Sabrina Giavara, Mark J O'Connor, Andrew N Tutt, Małgorzata Z Zdzienicka,[...]. Cancer Res 2006
831
25


Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.
Ellen Warner, Donald B Plewes, Kimberley A Hill, Petrina A Causer, Judit T Zubovits, Roberta A Jong, Margaret R Cutrara, Gerrit DeBoer, Martin J Yaffe, Sandra J Messner,[...]. JAMA 2004
762
25


Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.
Mohamed Salhab, Selina Bismohun, Kefah Mokbel. BMC Womens Health 2010
41
25

CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice.
Eun-Hee Kim, Chuxia Deng, Michael B Sporn, Darlene B Royce, Renee Risingsong, Charlotte R Williams, Karen T Liby. Cancer Prev Res (Phila) 2012
39
25

Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
Tomasz M Beer, Christopher W Ryan, Peter M Venner, Daniel P Petrylak, Gurkamal S Chatta, J Dean Ruether, Kim N Chi, James Young, W David Henner. Cancer 2008
78
25

Exemestane for primary prevention of breast cancer in postmenopausal women.
Yang Zhang, Katherine Simondsen, Jill M Kolesar. Am J Health Syst Pharm 2012
6
25

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Trevor J Powles, Sue Ashley, Alwynne Tidy, Ian E Smith, Mitch Dowsett. J Natl Cancer Inst 2007
267
25


BRCA1 and BRCA2: different roles in a common pathway of genome protection.
Rohini Roy, Jarin Chun, Simon N Powell. Nat Rev Cancer 2011
726
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.